[go: up one dir, main page]

IN2014MU00118A - - Google Patents

Download PDF

Info

Publication number
IN2014MU00118A
IN2014MU00118A IN118MU2014A IN2014MU00118A IN 2014MU00118 A IN2014MU00118 A IN 2014MU00118A IN 118MU2014 A IN118MU2014 A IN 118MU2014A IN 2014MU00118 A IN2014MU00118 A IN 2014MU00118A
Authority
IN
India
Prior art keywords
phenoxyphosphinyl
isopropoxycarbonyl
adenine
methoxy
propyl
Prior art date
Application number
Inventor
Siva Ram Prasad Vellanki
Raja Babu Balusu
Subba Rayudu Putta
Mastan Rao Raavi
Sivalakshmi Devi Arikatla
Original Assignee
Mylan Lab Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mylan Lab Ltd filed Critical Mylan Lab Ltd
Priority to PCT/IB2015/050239 priority Critical patent/WO2015107451A2/en
Priority to IN118MU2014 priority patent/IN2014MU00118A/en
Priority to EP15705378.6A priority patent/EP3077404B1/en
Priority to ES15705378T priority patent/ES2842123T3/en
Publication of IN2014MU00118A publication Critical patent/IN2014MU00118A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

The present disclosure provides process for the purification of 9-{(R)-2-[((R,S)-{[(S)-l-(isopropoxycarbonyl)ethyl]amino} phenoxyphosphinyl) methoxy] propyl}adenine using acids to give enantiomerically pure tenofovir alafenamide.
IN118MU2014 2014-01-14 2015-01-13 IN2014MU00118A (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
PCT/IB2015/050239 WO2015107451A2 (en) 2014-01-14 2015-01-13 Purification of tenofovir alafenamide and its intermediates
IN118MU2014 IN2014MU00118A (en) 2014-01-14 2015-01-13
EP15705378.6A EP3077404B1 (en) 2014-01-14 2015-01-13 Purification of tenofovir alafenamide and its intermediates
ES15705378T ES2842123T3 (en) 2014-01-14 2015-01-13 Purification of tenofovir alafenamide and its intermediates

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN118MU2014 IN2014MU00118A (en) 2014-01-14 2015-01-13

Publications (1)

Publication Number Publication Date
IN2014MU00118A true IN2014MU00118A (en) 2015-08-28

Family

ID=52484522

Family Applications (1)

Application Number Title Priority Date Filing Date
IN118MU2014 IN2014MU00118A (en) 2014-01-14 2015-01-13

Country Status (4)

Country Link
EP (1) EP3077404B1 (en)
ES (1) ES2842123T3 (en)
IN (1) IN2014MU00118A (en)
WO (1) WO2015107451A2 (en)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ2015384A3 (en) * 2015-06-05 2016-12-14 Zentiva, K.S. Tenofovir alafenamide solid forms
US9777028B2 (en) 2015-06-17 2017-10-03 Gilead Sciences, Inc. Co-crystals, salts and solid forms of tenofovir alafenamide
CN106699812A (en) * 2015-11-12 2017-05-24 江苏豪森药业集团有限公司 Method for preparation and purification of tenofovir prodrug
WO2017118928A1 (en) 2016-01-06 2017-07-13 Lupin Limited Process for the separation of diastereomers of tenofovir alafenamide
EP3411378B1 (en) 2016-02-02 2020-03-25 Sandoz AG Crystalline forms of tenofovir alafenamide monofumarate
CN107179355B (en) * 2016-03-11 2021-08-10 广东东阳光药业有限公司 Method for separating and detecting tenofovir alafenamide and related substances thereof
CZ2016156A3 (en) * 2016-03-17 2017-09-27 Zentiva, K.S. The method of preparation of diastereomerically pure Tenofovir Alafenamide or its salts
CN107226826A (en) * 2016-03-25 2017-10-03 江苏奥赛康药业股份有限公司 Tenofovir Chinese mugwort draws phenol amine fumarate compound and its pharmaceutical composition
CN106478725B (en) * 2016-10-14 2018-11-09 上海礼泰医药科技有限公司 The preparation method and applications of high-purity phosphine the third tenofovir intermediate
CN113072583A (en) * 2016-11-28 2021-07-06 正大天晴药业集团股份有限公司 Crystal of tenofovir alafenamide hemifumarate and preparation method thereof
CN108341841B (en) * 2017-01-22 2020-07-17 成都倍特药业股份有限公司 Salt of tenofovir alafenamide and aspartic acid
TWI714820B (en) * 2017-01-31 2021-01-01 美商基利科學股份有限公司 Crystalline forms of tenofovir alafenamide
CN106946935B (en) * 2017-04-28 2020-01-07 福建广生堂药业股份有限公司 Preparation method of diastereoisomer nucleoside derivative
CN109942632B (en) * 2017-12-20 2021-08-31 上海博志研新药物研究有限公司 Preparation method of tenofovir alafenamide intermediate
CN109942633B (en) * 2017-12-20 2021-08-31 上海新礼泰药业有限公司 Preparation method of tenofovir alafenamide intermediate
CN108467410B (en) * 2018-04-09 2021-04-09 重庆三圣实业股份有限公司 Preparation method, product and application of TAF intermediate
CN108484672A (en) * 2018-05-23 2018-09-04 中国药科大学制药有限公司 The chiral separation method of the third tenofovir of phosphorus
CN110283208B (en) * 2018-06-22 2022-07-08 南京济群医药科技股份有限公司 Chiral resolution method of tenofovir alafenamide
CN110105392A (en) * 2019-06-04 2019-08-09 石家庄凯赛医药科技有限公司 What a kind of tenofovir Chinese mugwort drew phenol amine efficiently synthesizes technique
EP4085062A1 (en) 2020-02-20 2022-11-09 Cipla Limited Novel salts and/or co-crystals of tenofovir alafenamide
US11667656B2 (en) 2021-01-27 2023-06-06 Apotex Inc. Crystalline forms of Tenofovir alafenamide
CN114907409A (en) * 2022-06-21 2022-08-16 辰欣药业股份有限公司 Preparation method of propofol tenofovir
KR20240109533A (en) * 2023-01-04 2024-07-11 주식회사 종근당 Pharmaceutical composition with improved stability comprising tenofovir alafenamide or pharmaceutically acceptable salts thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5798340A (en) * 1993-09-17 1998-08-25 Gilead Sciences, Inc. Nucleotide analogs
EE05366B1 (en) * 2000-07-21 2010-12-15 Gilead Sciences, Inc Prodrugs and Screening Methods for Phosphonate Nucleotide Analogs
CN101712692A (en) * 2009-12-21 2010-05-26 巢杰 Medicinal acid addition salt of tenofovir disoproxil fumarate and preparation method and medicinal application thereof
KR102033802B1 (en) * 2011-10-07 2019-10-17 길리애드 사이언시즈, 인코포레이티드 Methods for preparing anti-viral nucleotide analogs
AU2012327170A1 (en) * 2012-02-03 2013-08-22 Gilead Sciences, Inc. Therapeutic compounds
US9676803B2 (en) * 2013-06-07 2017-06-13 Cipla Limited Efficient process for separation of diastereomers of 9-[(R)-2-[[(R,S)-[[(S)-1-(isopropoxycarbonyl)ethyl]amino]-phenoxyphosphinyl]methoxy]propyl]adenine

Also Published As

Publication number Publication date
EP3077404B1 (en) 2020-10-07
WO2015107451A3 (en) 2015-12-10
ES2842123T3 (en) 2021-07-12
EP3077404A2 (en) 2016-10-12
WO2015107451A2 (en) 2015-07-23

Similar Documents

Publication Publication Date Title
IN2014MU00118A (en)
CR20140204A (en) METHODS TO PREPARE ANTIVIRAL NUCLEOTYTIC ANALOGS
IN2013MU01967A (en)
MX2021013118A (en) Polyfluorinated compounds acting as bruton's tyrosine kinase inhibitors.
EP3995581A3 (en) Oligonucleotide compounds for treatment of preeclampsia and other angiogenic disorders
AU2015208932A8 (en) (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase I inhibitors
EP3778605A3 (en) Lrrk2 inhibitors and methods of making and using the same
PH12016501192A1 (en) Tetrahydropyridopyrazines modulators of gpr6
MX2021014663A (en) Compound targeting il-23a and tnf-alpha and uses thereof.
HK1256033A1 (en) Use of peptides to stimulate the immune system
AU2015261096A8 (en) Process for preparing phosphorus-containing cyanohydrins
MY191352A (en) Aldosterone synthase inhibitors
GEP201706626B (en) Synthesis of (s)-nifuratel
IN2014MU00455A (en)
HUE049661T2 (en) Process for the purification of biomass hydrolysate
WO2015168617A3 (en) Compositions and methods for modulating mtorc1
MX2017012342A (en) FUSIONED BICYCLE COMPOUNDS FOR THE TREATMENT OF DISEASES.
PH12014501327A1 (en) Processes for making magnolol analogs
MX2017012027A (en) Deamination of organophosphorus-nucleosides.
EP3549582A3 (en) Novel capsazepine analogs for the treatment of cancer and other proliferative diseases
UA103197C2 (en) Use of nifurtimox for the treatment of diseases caused by trichomonadida
MX2019002017A (en) Sofosbuvir derivatives for the treatment of hepatitis c.
MX2017003415A (en) A tetrahydropyrrolo[3,4-d][1,3]thiazine-derivative as bace inhibitor.
MX388587B (en) Process for the preparation of 4-amino-1-((1s,4r, 5s)-2-fluoro-4,5-dihydroxy-3-hydroxymethyl-cyclopent-2-enyl)-1h-pyrimidin-2-one
MY194906A (en) Method for obtaining crystalline l-alanine